{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T02:03:10Z","timestamp":1767837790696,"version":"3.49.0"},"reference-count":39,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2009,8,26]],"date-time":"2009-08-26T00:00:00Z","timestamp":1251244800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2010,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Adalimumab (ADA) and certolizumab pegol (CZP) have demonstrated efficacy in Crohn\u2019s disease (CD) patients previously treated with infliximab (IFX).<\/jats:p><jats:p><jats:bold>Aim\u2002<\/jats:bold> To assess the efficacy and tolerability of a third anti\u2010TNF in CD after failure of and\/or intolerance to two different anti\u2010TNF antibodies.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> Crohn\u2019s disease patients who received ADA or CZP after loss of response and\/or intolerance to two anti\u2010TNF agent were included in this retrospective study. Data were collected using a standardized questionnaire. Clinical response, duration, safety and reasons for discontinuation were assessed.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Sixty\u2010seven patients treated with CZP (<jats:italic>n<\/jats:italic>\u2003=\u200340) or ADA (<jats:italic>n<\/jats:italic>\u2003=\u200327) were included. A clinical response was observed in 41 (61%) at week 6 and 34 patients (51%) at week 20. The probability of remaining under treatment at 3\u2003months, 6\u2003months and 9\u2003months was 68%, 60% and 45%, respectively. At the end of follow\u2010up, the third anti\u2010TNF had been stopped in 36 patients for intolerance (<jats:italic>n<\/jats:italic>\u2003=\u200313), or failure (<jats:italic>n<\/jats:italic>\u2003=\u200323). Two deaths were observed.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> The treatment with a third anti\u2010TNF (CZP or ADA) agent of CD patients, who have experienced loss of response and\/or intolerance to two anti\u2010TNF antibodies, has favourable short\u2010term and long\u2010term efficacy. It is an option to be considered in patients with no other therapeutic options.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2009.04130.x","type":"journal-article","created":{"date-parts":[[2009,8,26]],"date-time":"2009-08-26T18:22:23Z","timestamp":1251310943000},"page":"92-101","source":"Crossref","is-referenced-by-count":93,"title":["The efficacy and safety of a third anti\u2010TNF monoclonal antibody in Crohn\u2019s disease after failure of two other anti\u2010TNF antibodies"],"prefix":"10.1111","volume":"31","author":[{"given":"M.","family":"ALLEZ","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"VERMEIRE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"MOZZICONACCI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"MICHETTI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"LAHARIE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"LOUIS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.\u2010A.","family":"BIGARD","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"H\u00c9BUTERNE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"TRETON","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"KOHN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"MARTEAU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"CORTOT","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"NICHITA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"VAN ASSCHE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"RUTGEERTS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"L\u00c9MANN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.\u2010F.","family":"COLOMBEL","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,12,2]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.40.4.443"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199710093371502"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08512-4"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199905063401804"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70332-X"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00025.x"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030815"},{"key":"e_1_2_7_9_2","first-page":"CD006893","article-title":"Tumor necrosis factor\u2010alpha antibody for maintenance of remission in Crohn\u2019s disease","author":"Behm B","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20177"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2003.018515"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020888"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.07457.x"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(04)00238-1"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2003.50145"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.11.030"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.106781"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.11.041"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062897"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067594"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.06.064"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2004.40462.x"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200407000-00002"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.40647.x"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2007.03254.x"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.03232.x"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-12-200706190-00159"},{"key":"e_1_2_7_28_2","first-page":"494","article-title":"Efficacy and safety of certolizumab pegol with active Crohn\u2019s disease who previously lost response or were intolerant to infliximab: open\u2010label induction preliminary results of the welcome study","volume":"67","author":"Vermeire S","year":"2008","journal-title":"Gastroenterology"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.155812"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(80)92767-1"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.039099"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar1881"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel054"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.009589"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1080\/03009740510026887"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20225"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.10.047"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2003.020552"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.01.012"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.087288"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2009.04130.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2009.04130.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T20:06:34Z","timestamp":1698782794000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2009.04130.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,2]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["10.1111\/j.1365-2036.2009.04130.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2009.04130.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12,2]]}}}